Evidence map›Paper›PMID 37922289›Full record

ArticlePloS one2023

Serum cytokines MCP-1 and GCS-F as potential biomarkers in pediatric inflammatory bowel disease.

Andrea Ott, Erol Tutdibi, Sybelle Goedicke-Fritz, Jakob Schöpe, Michael Zemlin, Nasenien Nourkami-Tutdibi

Open access · goldAbstract read
In one paragraph

Article in PloS one, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
2.5field-weighted citation impact, top 10% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 8 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Prophylactic effects ofBiomedical reports · 2026
    Article
  5. A novel diagnostic serum protein signature for pediatric inflammatory bowel disease.Journal of pediatric gastroenterology and nutrition · 2026
    Observational
  6. Article
  7. Article
  8. Article
  9. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 1 institution in 1 country.

Andrea OttHospital for General Pediatrics and Neonatology, Saarland University Medical Center, Homburg/Saar, Germany.
Erol TutdibiHospital for General Pediatrics and Neonatology, Saarland University Medical Center, Homburg/Saar, Germany.ORCID 0000-0002-1866-4492
Sybelle Goedicke-FritzHospital for General Pediatrics and Neonatology, Saarland University Medical Center, Homburg/Saar, Germany.
Jakob SchöpeInstitute of Medical Biometry, Epidemiology and Medical Informatics, Saarland University, Homburg/Saar, Germany.
Michael ZemlinHospital for General Pediatrics and Neonatology, Saarland University Medical Center, Homburg/Saar, Germany.
Nasenien Nourkami-TutdibiHospital for General Pediatrics and Neonatology, Saarland University Medical Center, Homburg/Saar, Germany.ORCID 0000-0003-4240-1868
Saarland University · DE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundInflammatory bowel diseases (IBDs) with the subtypes ulcerative colitis (UC) and Crohn disease (CD), are chronic autoimmune inflammatory disorders of the gastrointestinal tract. Cytokines are associated with the development and progression in pediatric IBD. We measured cytokine levels in pediatric IBD patients to assess their potential function as biomarkers in disease assessment.

methodIn this prospective cohort study, we enrolled 33 children with IBD. All patients were in stable remission for 3 months on enrollment. Patients who developed a relapse within six months after enrollment were classified as relapsers. Blood sampling was performed at enrolment and for relapsers in relapse and post-relapse. Serum concentrations of 14 cytokines, chemokines and growth factors (IL-1α, IL-1β, IL-6, IL-12p40, IP-10, TNF-α, IFN-γ, IL-10, IL-8, MIP-1α, MCP-1, MCP-3, G-CSF, GM-CSF) were measured simultaneously using multiplex bead-based sandwich immunoassay on Luminex 100 system.

resultsMCP-1 was significantly higher in CD patients compared to UC patients at each disease stage: stable remission (P<0.048), unstable remission (P<0.013), relapse (P<0.026) and post-relapse (P<0.024). G-CSF was significantly increased in UC patients developing a relapse and in post-relapse stage compared to UC patients in remission (P<0.02 and p<0.03, respectively).

conclusionMCP-1 showed potential as a diagnostic biomarker in CD patients independent of disease activity as it was able to discriminate between subtypes of pediatric IBD. In UC patients, G-CSF was significantly elevated in relapsers indicating its use and role as a potential prognostic biomarker.

Indexed as

Colitis, UlcerativeCrohn DiseaseInflammatory Bowel DiseasesBiomarkersChemokine CCL2ChildCytokinesGranulocyte Colony-Stimulating FactorHumansProspective StudiesRecurrenceBiomarkersCCL2 protein, humanChemokine CCL2CytokinesGranulocyte Colony-Stimulating Factor

Identifiers

PMID37922289
PMCPMC10624322
OpenAlexW4388286797

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.